Hantavirus vaccine in 2026?
Weather · market-implied 11.5%
Recent price
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market summary
This market is currently priced at 11.5%, while BinaryStreaks estimates fair value at 12.5%, indicating a possible +1.0 percentage point difference.
Why this is flagged: Δ6h +4.0 pts · Δ24h +4.0 pts (same direction)
What this means
- This may indicate the market is repricing new information, or reacting to liquidity and order flow.
- Signals are informational only and not trading advice.
- BinaryStreaks uses public market data and deterministic, rule-based analysis.
Related markets
- Hantavirus pandemic in 2026?
- Confirmed case of Hantavirus in US by May 15?
- Will there be 8 or more earthquakes of magnitude 7.0 or higher worldwide by June 30?
- Will there be exactly 0 confirmed VEI 4 or higher volcanic eruptions worldwide in 2026?
- Will there be exactly 5 earthquakes of magnitude 7.0 or higher worldwide by June 30?
- Will there be between 11 and 13 earthquakes of magnitude 7.0 or higher worldwide in 2026?
Execution
YES
NO